- Home
- TNGX vs LAB Comparison
TNGX vs LAB Comparison
Compare TNGX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- LAB
- Stock Information
- Founded
- TNGX 2014
- LAB 1999
- Country
- TNGX United States
- LAB United States
- Employees
- TNGX N/A
- LAB N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- TNGX Health Care
- LAB Industrials
- Exchange
- TNGX Nasdaq
- LAB Nasdaq
- Market Cap
- TNGX 351.2M
- LAB 372.1M
- IPO Year
- TNGX N/A
- LAB 2011
- Fundamental
- Price
- TNGX $5.16
- LAB $1.05
- Analyst Decision
- TNGX Strong Buy
- LAB Buy
- Analyst Count
- TNGX 6
- LAB 2
- Target Price
- TNGX $12.20
- LAB $2.50
- AVG Volume (30 Days)
- TNGX 3.9M
- LAB 1.3M
- Earning Date
- TNGX 08-06-2025
- LAB 07-30-2025
- Dividend Yield
- TNGX N/A
- LAB N/A
- EPS Growth
- TNGX N/A
- LAB N/A
- EPS
- TNGX N/A
- LAB N/A
- Revenue
- TNGX $40,990,000.00
- LAB $169,687,000.00
- Revenue This Year
- TNGX N/A
- LAB N/A
- Revenue Next Year
- TNGX N/A
- LAB $12.18
- P/E Ratio
- TNGX N/A
- LAB N/A
- Revenue Growth
- TNGX 10.09
- LAB 33.86
- 52 Week Low
- TNGX $1.03
- LAB $0.92
- 52 Week High
- TNGX $12.02
- LAB $2.41
- Technical
- Relative Strength Index (RSI)
- TNGX 79.99
- LAB 48.48
- Support Level
- TNGX $4.40
- LAB $1.02
- Resistance Level
- TNGX $5.37
- LAB $1.12
- Average True Range (ATR)
- TNGX 0.65
- LAB 0.07
- MACD
- TNGX 0.10
- LAB 0.00
- Stochastic Oscillator
- TNGX 93.68
- LAB 46.67
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.